API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
https://www.prnewswire.com/news-releases/passport-technologies-inc-announces-positive-interim-phase-i-results-of-zolmitriptan-transdermal-microporation-system-for-the-treatment-of-acute-migraine-302103063.html
https://www.prnewswire.com/news-releases/passport-technologies-inc-initiated-us-phase-i-clinical-trial-of-zolmitriptan-transdermal-microporation-system-for-the-treatment-of-acute-migraine-302070038.html
https://www.bizjournals.com/sanfrancisco/news/2022/04/29/migraine-patch-job-cuts-fda-zosano-zsan-qtrypta.html
https://www.benzinga.com/general/biotech/22/02/25745155/fda-rejects-zosano-pharmas-application-for-zolmitriptan-microneedle-system-again-shares-plunge
https://www.prnewswire.com/news-releases/padagis-announces-the-first-to-market-launch-of-an-ab-rated-generic-version-of-zomig-nasal-spray-301425925.html
https://www.prnewswire.com/news-releases/padagis-announces-the-first-to-market-launch-of-an-ab-rated-generic-version-of-zomig-nasal-spray-301425925.html
https://www.clinicaltrialsarena.com/news/zosano-pharma-cluster-headache-trial/
https://seekingalpha.com/news/3509144-zosano-launches-phase-2-3-study-zolmitriptan-cluster-headache
https://www.biospace.com/article/releases/zosano-pharma-initiates-phase-2-3-clinical-study-in-cluster-headacheadvances-second-late-stage-program-for-adam-microneedle-technology/?s=95
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203726
https://www.biopharmadive.com/news/astrazeneca-sell-off-deal-covis-respiratory/541614/
https://endpts.com/astrazeneca-hands-over-some-rights-to-nexium-vimovo-to-grunenthal-as-its-plots-turnaround/
https://globenewswire.com/news-release/2018/09/26/1576485/0/en/Zosano-Pharma-Enters-Into-Capital-Equipment-Lease-Agreement-With-Trinity-Capital-Investment.html
https://www.prnewswire.com/news-releases/amneal-announces-favorable-ruling-regarding-patent-validity-for-zomig-zolmitriptan-nasal-spray-300674602.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206973
http://www.pharmatimes.com/news/az_divests_migraine_drug_to_grunenthal_1194949
http://www.prnewswire.com/news-releases/impax-announces-favorable-ruling-regarding-patent-validity-for-zomig-zolmitriptan-nasal-spray-300432224.html
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207867
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alembic-pharma-gets-us-fda-nod-for-anti-migraine-drug/articleshow/55805818.cms
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205074
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/ajanta-pharma-gets-usfda-nod-for-migraine-pain-relief-drug/articleshow/52413191.cms
https://www.pharmacompass.com/pdf/news/aurobindo-pharmas-generic-zolmitriptan-approved-in-us-as-treatment-of-migraine-1463220479.pdf
https://www.pharmacompass.com/pdf/news/macleods-generic-zolmitriptan-25mg-approved-in-us-for-migraines-1443869242.pdf
http://www.thestreet.com/story/13010593/1/impax-laboratories-expects-more-ma-after-latest-deal-closes.html